EXCLUSIVE ONLINE CONTENT

11/27/2018

Evelo & Merck Enter Clinical Trial Collaboration

Evelo Biosciences, Inc. recently announced it has entered into a clinical trial collaboration agreement with Merck. The collaboration will evaluate EDP1503 in combination with KEYTRUDA (pembrolizumab).

11/21/2018

Cambrex to Acquire Avista Pharma Solutions

Cambrex Corporation recently announced it has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.

11/21/2018

Roivant Sciences & iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic; Deal Worth $667.5 Milllion

Roivant Sciences and iNtRON Biotechnology recently announced they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic-resistant staphylococci. This licensing deal is worth a total of $667.5 million inclusive of milestone payments, with royalties on net sales in the low double digits.